Home
About
News
- News

Contact US

Our research on drug repurposing for the improved therapy in TP53-mutated AML was awarded.

Jun 20, 2021

Our group is awarded a prize sum of 50.000 SEK from the Cathrine Everts foundation for the study "Drug repurposing to reactivate p53 protein family for improved therapy in TP53-mutated acute myeloid leukemia (AML)".

Link to Cathrine Everts Forskningsstiftelse press release.
Link to Karolinska Institute press release.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories

Essential

On

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

On

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.